Fitting methods for intravoxel incoherent motion imaging of prostate cancer on region of interest level: Repeatability and gleason score prediction

: Harri Merisaari, Parisa Movahedi, Ileana M. Perez, Jussi Toivonen, Marko Pesola, Pekka Taimen, Peter J. Boström, Tapio Pahikkala, Aida Kiviniemi, Hannu J. Aronen, Ivan Jambor

: 2017

: Magnetic Resonance in Medicine

: Magnetic resonance in medicine

: Magn Reson Med

: 77

: 3

: 1249

: 1264

: 16

: 1522-2594

DOI: https://doi.org/10.1002/mrm.26169

PURPOSE
To evaluate different fitting methods for intravoxel incoherent motion (IVIM) imaging of prostate cancer in the terms of repeatability and Gleason score prediction.
METHODS
Eighty-one patients with histologically confirmed prostate cancer underwent two repeated 3 Tesla diffusion-weighted imaging (DWI) examinations performed using 14 b-values in the range of 0-500 s/mm(2) and diffusion time of 19.004 ms. Mean signal intensities of regions-of-interest were fitted using five different fitting methods for IVIM as well as monoexponential, kurtosis, and stretched exponential models. The fitting methods and models were evaluated in the terms of fitting quality [Akaike information criteria (AIC)], repeatability, and Gleason score prediction. Tumors were classified into three groups (3 + 3, 3 + 4, > 3 + 4). Machine learning algorithms were used to evaluate the performance of the combined use of the parameters. Simulation studies were performed to evaluate robustness of the fitting methods against noise.
RESULTS
Monoexponential model was preferred over IVIM based on AIC. The "pseudodiffusion" parameters demonstrated low repeatability and clinical value. Median "pseudodiffusion" fraction values were below 8.00%. Combined use of the parameters did not outperform the monoexponential model.
CONCLUSION
Monoexponential model demonstrated the highest repeatability and clinical values in the regions-of-interest based analysis of prostate cancer DWI, b-values in the range of 0-500 s/mm(2) . Magn Reson Med, 2016. © 2016 Wiley Periodicals, Inc.